🚨 𝗟𝗔𝗦𝗧 𝗖𝗔𝗟𝗟 🚨 Join us tomorrow for our virtual event, 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘄𝗶𝘁𝗵 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 – 𝘄𝗵𝗲𝗿𝗲 𝘄𝗲 𝘂𝗻𝘃𝗲𝗶𝗹 𝗠𝘅𝗣® 𝗤𝘂𝗮𝗻𝘁 𝟭𝟬𝟬𝟬 𝗮𝘀𝘀𝗮𝘆, the new standard in quantitative metabolomics. Metabolomics is already advancing biomedical research, pathway analysis, and microbiome-host insights. 𝗕𝘂𝘁 𝗵𝗼𝘄 𝗰𝗮𝗻 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀 𝗳𝘂𝗹𝗹𝘆 𝗵𝗮𝗿𝗻𝗲𝘀𝘀 𝗶𝘁𝘀 𝗽𝗼𝘄𝗲𝗿❓ 💡 𝗠𝘅𝗣® 𝗤𝘂𝗮𝗻𝘁 𝟭𝟬𝟬𝟬 𝗮𝘀𝘀𝗮𝘆 𝘁𝗮𝗸𝗲𝘀 𝗾𝘂𝗮𝗻𝘁𝗶𝘁𝗮𝘁𝗶𝘃𝗲 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗹𝗲𝘃𝗲𝗹. Built on 20+ years of expertise, it enables the analysis of 1,200+ analytes across 49 biochemical classes – delivering instant insights through standardized workflows and AI-powered data analysis. 🎤 𝗘𝘅𝗽𝗲𝗿𝘁 𝘀𝗽𝗲𝗮𝗸𝗲𝗿𝘀 🔹 Alice Limonciel, Ph.D. – Chief Scientific Officer, biocrates life sciences ag 🔹 Markus Langsdorf, Ph.D. – Product Manager, biocrates life sciences ag 📅 April 03, 2025 | 🕔 05:00 pm CET | 💻 Virtual 🔒 𝗦𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁 𝗻𝗼𝘄 𝗮𝗻𝗱 𝗯𝗲 𝗮𝗺𝗼𝗻𝗴 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝘁𝗼 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝗼𝘂𝗿 𝗺𝗼𝘀𝘁 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗮𝘀𝘀𝗮𝘆 𝘆𝗲𝘁 👉https://zurl.co/sc20g #Metabolomics #PrecisionMedicine #Innovation #Research
biocrates life sciences ag
Biotechnologieforschung
The future of research and health
Info
biocrates is the global leader in mass spectrometry-based quantitative metabolite analysis, with kits and assays covering over 1,000+ metabolites from more than 40 metabolite classes. Our platform combines innovative technology for sample preparation, metabolite identification, and data analysis. The use of quantitative, standardized, and quality-controlled metabolomics methods guarantees robust and reproducible results that are the cornerstones of all clinical research. From just a few microliters of sample material, we can uncover the entire phenotype of an individual and answer a host of questions about systems biology.
- Website
-
https://biocrates.com
Externer Link zu biocrates life sciences ag
- Branche
- Biotechnologieforschung
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Innsbruck
- Art
- Privatunternehmen
- Gegründet
- 2002
- Spezialgebiete
- Targeted Metabolomics, Bioinformatics, Clinical Research & Clinical Diagnostics, Personalized Medicine, Cancer Research, Metabolomics Services, BioProcessing, Microbiome Research, Metabolite Quantification und Functional Microbiomics
Orte
-
Primär
Eduard-Bodem-Gasse 8
Innsbruck, AT
Beschäftigte von biocrates life sciences ag
Updates
-
📢 The recordings from the virtual event, 𝗠𝘂𝗹𝘁𝗶𝗼𝗺𝗶𝗰𝘀 – 𝗧𝗵𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗼𝗳 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄 𝗮𝘁 𝘆𝗼𝘂𝗿 𝗳𝗶𝗻𝗴𝗲𝗿𝘁𝗶𝗽𝘀, are now available on YouTube! 𝗗𝗶𝗱 𝘆𝗼𝘂 𝗺𝗶𝘀𝘀 𝘁𝗵𝗲 𝗹𝗶𝘃𝗲 𝗲𝘃𝗲𝗻𝘁 𝗼𝗻 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟱, 𝗼𝗿 𝗱𝗼 𝘆𝗼𝘂 𝘄𝗮𝗻𝘁 𝘁𝗼 𝗱𝗶𝘃𝗲 𝗯𝗮𝗰𝗸 𝗶𝗻𝘁𝗼 𝗸𝗲𝘆 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝘀𝗵𝗮𝗿𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘄𝗶𝘁𝗵 𝗳𝗲𝗹𝗹𝗼𝘄 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀? The recordings are now ready for you to explore! 💡 🧩 The expert speakers shared valuable insights on how omics are leveraged in today's biomedical research and the added value of metabolomics in a multiomics approach. 🎙️Asst. Prof. Spencer Rosario – Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer 👉 https://zurl.co/JGVsA 🎙️ Juozas Gordevicius, Ph.D. – Unraveling disease mechanics through multi-omic integration: Insights from metabolomics and beyond 👉 https://zurl.co/f3t3E 🎙️ Alice Limonciel, Ph.D. – Multiomics for 5P medicine 👉 https://zurl.co/jubNM 🎥 Access the full playlist here 👉 https://zurl.co/qM2y8 Explore these eye-opening talks and take your understanding of multiomics to the next level! 🚀 #Metabolomics #Multiomics #Webinar #Innovation
-
-
🎧 𝗧𝗵𝗲 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝘀𝘁 𝗽𝗼𝗱𝗰𝗮𝘀𝘁 𝗿𝗲𝘁𝘂𝗿𝗻𝘀 – 𝘀𝗲𝗮𝘀𝗼𝗻 𝟰 𝗹𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗔𝗽𝗿𝗶𝗹 𝟬𝟭, 𝟮𝟬𝟮𝟱! 🎧 💡 We’re soon back with a new season of The Metabolomist – the podcast where metabolomics scientists share their stories, challenges, and passion for small molecules and lipids. 🩺 𝗦𝗲𝗮𝘀𝗼𝗻 𝟰 𝗲𝘅𝗽𝗹𝗼𝗿𝗲𝘀 𝗼𝗻𝗲 𝗯𝗶𝗴 𝘁𝗵𝗲𝗺𝗲 – 𝟱𝗣 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘄𝗶𝘁𝗵 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 Tune in as our guests dive into the science, the hurdles, and the real-world impact of metabolomics in shaping the future of healthcare. 🚀 🎙️ While you wait, catch up on season 3, where Alice Limonciel spoke with: 🔹 Robert Nagourney, MD on personalized medicine & survival prediction 🔹 Sabine Bahn on physical markers & treatment of mental illness 🔹 Vadim Gladyshev on aging fluidity & omics signatures 🔹 Marc-Emmanuel Dumas on phenomics & microbiome 🔹 Sandi Azab on metabolomic epidemiology & childhood obesity 🔹 Audrey LE GOUELLEC on bacterial metabotypes & the medicine of tomorrow 📩 𝗪𝗮𝗻𝘁 𝗽𝗼𝗱𝗰𝗮𝘀𝘁 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝗲𝗱 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗶𝗻𝗯𝗼𝘅? 𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝗵𝗲𝗿𝗲 👉 https://lnkd.in/dnMJMkJE 🎧𝗟𝗶𝘀𝘁𝗲𝗻 𝘁𝗼 𝗧𝗵𝗲 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝘀𝘁 𝗵𝗲𝗿𝗲 👉 https://zurl.co/Ds1zH #TheMetabolomist #Metabolomics #5Pmedicine #Healthcare
-
𝗪𝗵𝗮𝘁’𝘀 𝗻𝗲𝘄 𝗶𝗻 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 ❓ 𝗙𝗶𝗻𝗱 𝗼𝘂𝘁 𝗶𝗻 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 🌟𝗚𝗼𝗼𝗱 𝗻𝗲𝘄𝘀 𝗳𝗿𝗼𝗺 𝗯𝗶𝗼𝗰𝗿𝗮𝘁𝗲𝘀🌟. Our monthly newsletter delivers exclusive insights, expert research, and event updates – straight to your inbox! 📧 This month's edition included: 🤝𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 Platomics Our new partnership integrates biocrates kits with the PlatoX® platform, making it easier than ever for labs to ensure quality, compliance, and reproducibility in metabolomics research. 🩺 𝗩𝗶𝗿𝘁𝘂𝗮𝗹 𝗹𝗮𝘂𝗻𝗰𝗵 𝗲𝘃𝗲𝗻𝘁 | 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘄𝗶𝘁𝗵 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰 Join our virtual launch on 𝗔𝗽𝗿𝗶𝗹 𝟯, 𝟮𝟬𝟮𝟱 to 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗠𝘅𝗣® 𝗤𝘂𝗮𝗻𝘁 𝟭𝟬𝟬𝟬 𝗮𝘀𝘀𝗮𝘆 – a new standard in quantitative metabolomics. Register here 👉https://zurl.co/aALIL 🧠 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘁𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗠𝗼𝗻𝘁𝗵 – 𝗡-𝗮𝗰𝗲𝘁𝘆𝗹-𝗮𝘀𝗽𝗮𝗿𝘁𝗶𝗰 𝗮𝗰𝗶𝗱 (𝗔𝗔) Discover the role of this key brain metabolite in neurological function, energy metabolism, and disease research. 🚀 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘄𝗶𝘁𝗵 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 (𝟮 | 𝟱) – 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝘃𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 Our 5P blog series continues with a deep dive into how broad metabolomics panels and knowledge-based tools support early risk detection and innovative strategies for predictive healthcare. 🔔 𝗪𝗮𝗻𝘁 𝗰𝗼𝗻𝘁𝗲𝗻𝘁 𝗹𝗶𝗸𝗲 𝘁𝗵𝗶𝘀 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝗲𝗱 𝗺𝗼𝗻𝘁𝗵𝗹𝘆? 𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝗻𝗼𝘄! 👉 https://zurl.co/uBnqG #Metabolomics #Collaboration #Loveyourmetabolites #PreventiveMedicine
-
-
🚀 𝗔 𝗻𝗲𝘄 𝗲𝗿𝗮 𝗶𝗻 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 𝗶𝘀 𝗵𝗲𝗿𝗲! 👀 📢 Join us for our virtual event, 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘄𝗶𝘁𝗵 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀, 𝘄𝗵𝗲𝗿𝗲 𝘄𝗲 𝗶𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗲 𝗠𝘅𝗣® 𝗤𝘂𝗮𝗻𝘁 𝟭𝟬𝟬𝟬 – 𝘁𝗵𝗲 𝗻𝗲𝘄 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗶𝗻 𝗾𝘂𝗮𝗻𝘁𝗶𝘁𝗮𝘁𝗶𝘃𝗲 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 that you won’t want to miss! Metabolomics already contributes to revolutionizing biomedical research, metabolic pathway analysis, and microbiome-host interactions. ❓ But how can researchers fully harness its potential? 💡 𝗠𝘅𝗣® 𝗤𝘂𝗮𝗻𝘁 𝟭𝟬𝟬𝟬 𝘀𝗲𝘁𝘀 𝗮 𝗻𝗲𝘄 𝗯𝗲𝗻𝗰𝗵𝗺𝗮𝗿𝗸 𝗶𝗻 𝗾𝘂𝗮𝗻𝘁𝗶𝘁𝗮𝘁𝗶𝘃𝗲 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴. Built on 20+ years of expertise, this cutting-edge assay enables the screening of 1,200+ analytes across 49 biochemical classes – delivering instant insights with standardized workflows and AI-powered data analysis. 🎤 𝗘𝘅𝗽𝗲𝗿𝘁 𝘀𝗽𝗲𝗮𝗸𝗲𝗿𝘀 🔹 Alice Limonciel, Ph.D. – Chief Scientific Officer, biocrates life sciences 🔹 Markus Langsdorf, Ph.D. – Product Manager, biocrates life sciences 📅 April 03, 2025 | 🕔 05:00 pm CET | 💻 Virtual 🔥 𝗕𝗲 𝗮𝗺𝗼𝗻𝗴 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝘁𝗼 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝗠𝘅𝗣® 𝗤𝘂𝗮𝗻𝘁 𝟭𝟬𝟬𝟬. 𝗦𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁 𝗻𝗼𝘄! 👉 https://zurl.co/sc20g #Metabolomics #PrecisionMedicine #Research #Innovation
-
🌿 Our metabolite of the month: 𝗡-𝗮𝗰𝗲𝘁𝘆𝗹-𝗮𝘀𝗽𝗮𝗿𝘁𝗶𝗰 𝗮𝗰𝗶𝗱 (𝗡𝗔𝗔)! 🌿 𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄 𝘁𝗵𝗮𝘁 𝗡𝗔𝗔, 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗮𝗯𝘂𝗻𝗱𝗮𝗻𝘁 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘁𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗯𝗿𝗮𝗶𝗻, 𝘄𝗮𝘀 𝗳𝗶𝗿𝘀𝘁 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗲𝗱 𝗶𝗻 𝟭𝟵𝟱𝟲? 🔎 Despite decades of research, its full role remains a biochemical mystery! ❓ 𝗪𝗵𝘆 𝗶𝘀 𝗡𝗔𝗔 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁? NAA plays a key role in neuronal metabolism, osmoregulation, myelin synthesis, and lipid metabolism, though its primary function remains debated. 🦠 It is also a crucial biomarker in brain imaging, with altered levels linked to Alzheimer’s, multiple sclerosis, and psychiatric disorders. ✨ 𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄? 🧠 NAA is 𝗽𝗿𝗶𝗺𝗮𝗿𝗶𝗹𝘆 𝘀𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘇𝗲𝗱 𝗶𝗻 𝗻𝗲𝘂𝗿𝗼𝗻𝗮𝗹 𝗺𝗶𝘁𝗼𝗰𝗵𝗼𝗻𝗱𝗿𝗶𝗮 from acetyl-CoA and aspartic acid by the enzyme N-acetylaspartate synthetase (NAT8L). 💡Click through the carousel below for more insights. 🩸 It serves as an acetate reservoir, 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗳𝗼𝗿 𝗹𝗶𝗽𝗶𝗱 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘀𝗺 in the brain. 📡 Its strong magnetic resonance spectroscopy (MRS) signal makes it a 𝗸𝗲𝘆 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗺𝗮𝗿𝗸𝗲𝗿. Changes in NAA levels have been associated with brain injuries, Alzheimer’s disease, multiple sclerosis, psychiatric disorders, and even cancer metabolism, making it a focus of cutting-edge research! 📖 𝗪𝗮𝗻𝘁 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝗡𝗔𝗔’𝘀 𝗿𝗼𝗹𝗲 𝗶𝗻 𝗻𝗲𝘂𝗿𝗼𝗹𝗼𝗴𝘆, 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘀𝗺, 𝗮𝗻𝗱 𝗱𝗶𝘀𝗲𝗮𝘀𝗲? Check the first comment to read the full article. #Metabolomics #Science #Loveyourmetabolites #Neurology
-
🚨 LAST CALL! 🚨 Don't miss your chance to join our virtual event 𝗛𝘂𝗺𝗮𝗻 𝗺𝗶𝗹𝗸 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 | 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝘁𝗼 𝗶𝗻𝗳𝗮𝗻𝘁 𝗻𝘂𝘁𝗿𝗶𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗵𝗲𝗮𝗹𝘁𝗵! 🍼 ❓ 𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄 𝗵𝘂𝗺𝗮𝗻 𝗺𝗶𝗹𝗸 𝗰𝗼𝗻𝘁𝗮𝗶𝗻𝘀 𝗵𝘂𝗻𝗱𝗿𝗲𝗱𝘀 𝗼𝗳 𝗯𝗶𝗼𝗮𝗰𝘁𝗶𝘃𝗲 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗳𝗼𝗿 𝗶𝗻𝗳𝗮𝗻𝘁 𝗵𝗲𝗮𝗹𝘁𝗵? 🔓Discover how metabolomics is unlocking its secrets and transforming our understanding of maternal and neonatal health. 📆 March 19, 2025 🕓 04:00 - 05:00 pm CET | 11:00 - 12:00 pm EST 📌 Virtual on ZOOM 🎤 Expert insights from 🔹 Teodoro Bottiglieri, Ph.D. – Target metabolomic analysis of human breast milk using the biocrates MxP Quant 500 platform 🔹 Daniela H., Ph.D. – Human milk targeted metabolomics ⏳ Only 1 day left – secure your spot now! 👉 https://zurl.co/6FOXI #Metabolomics #Health #Nutrition #Research
-
-
🍼 𝗛𝘂𝗺𝗮𝗻 𝗺𝗶𝗹𝗸 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗶𝗻 𝘁𝗵𝗲 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁! 🔬 ❓ 𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄 𝘁𝗵𝗮𝘁 𝗯𝗿𝗲𝗮𝘀𝘁 𝗺𝗶𝗹𝗸’𝘀 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗲𝘅𝘁𝗲𝗻𝗱 𝗯𝗲𝘆𝗼𝗻𝗱 𝗶𝗻𝗳𝗮𝗻𝘁𝘀? Last September, The Economist highlighted the incredible benefits of breast milk. We are proud that biocrates technology contributed to the key study with the International Consortium for Milk Composition (#IMiC) 🔬 𝗪𝗵𝗮𝘁 𝗱𝗶𝗱 The Economist 𝗿𝗲𝗽𝗼𝗿𝘁 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝘀𝘁𝘂𝗱𝘆? Researchers analyzed 1,200 milk samples across three continents, detecting 50,000 small molecules, many previously unknown. AI-driven analysis is now linking these molecules to maternal and infant health data. 📢 𝗪𝗮𝗻𝘁 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲? Join our 𝗛𝘂𝗺𝗮𝗻 𝗺𝗶𝗹𝗸 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 virtual event to explore how metabolomics is transforming our understanding of breast milk’s role in infant health. 📅 March 19, 2025 🕓04:00 - 05:00 PM CET | 11:00 - 12:00 AM EST 📌 Virtual on ZOOM 🎤Speakers | Teodoro Bottiglieri, Ph.D., Daniela H., Ph.D. 𝗦𝗮𝘃𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁 𝗻𝗼𝘄 👉https://zurl.co/Uhs6N 🔗 The Economist article "Breast milk’s benefits are not limited to babies": https://zurl.co/Y15uf #Metabolomics #Health #BreastMilk #Research
-
-
Metabolite History 🌟 𝗔𝘀𝘆𝗺𝗺𝗲𝘁𝗿𝗶𝗰 𝗗𝗶𝗺𝗲𝘁𝗵𝘆𝗹 𝗔𝗿𝗴𝗶𝗻𝗶𝗻𝗲 (𝗔𝗗𝗠𝗔) 🌟 📜 𝗘𝘃𝗲𝗿 𝘄𝗼𝗻𝗱𝗲𝗿𝗲𝗱 𝗵𝗼𝘄 𝗮 𝘀𝗶𝗻𝗴𝗹𝗲 𝗺𝗼𝗱𝗶𝗳𝗶𝗲𝗱 𝗮𝗺𝗶𝗻𝗼 𝗮𝗰𝗶𝗱 𝗰𝗮𝗻 𝗶𝗺𝗽𝗮𝗰𝘁 𝗰𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿, 𝗻𝗲𝘂𝗿𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹, 𝗮𝗻𝗱 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗵𝗲𝗮𝗹𝘁𝗵? Meet ADMA – a key regulator of nitric oxide (NO) signaling and a biomarker of endothelial dysfunction. 🔎 𝗙𝗶𝗿𝘀𝘁 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝗱 𝗶𝗻 𝗵𝘂𝗺𝗮𝗻 𝘂𝗿𝗶𝗻𝗲 𝗶𝗻 𝟭𝟵𝟳𝟬 (Kakimoto & Akazawa 1970), ADMA gained attention in 1992 when its role as an inhibitor of nitric oxide synthase (NOS) was discovered (Leone et al. 1992). This finding linked ADMA to vascular health, as NO is essential for blood vessel relaxation and function. 🔬 ADMA is generated by PRMT enzymes through arginine methylation and released during protein degradation. It competes with arginine, inhibiting NO synthesis and affecting blood flow, neurotransmission, and immunity. About 20% is excreted in urine, while 80% is degraded enzymatically by DDAH and AGTX2, maintaining vascular and metabolic balance. 🩸 𝗘𝗻𝗱𝗼𝘁𝗵𝗲𝗹𝗶𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵 – Elevated ADMA levels are associated with hypertension, diabetes, deep vein thrombosis, congenital heart disease, and other cardiometabolic diseases due to impaired NO production and endothelial dysfunction. 🧠 𝗡𝗲𝘂𝗿𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗶𝗺𝗽𝗮𝗰𝘁 – Increased ADMA has been linked to Parkinson’s disease, stroke, and depression, likely through its effects on neuronal NOS and neurotransmission, though evidence on NOS activity in depression remains mixed. ⚖️ 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗿𝗼𝗹𝗲 – As a uremic toxin, ADMA clearance is vital for kidney function. Elevated levels contribute to metabolic diseases, inflammation, and oxidative stress. As research into ADMA continues, its role as a biomarker for chronic diseases underscores the importance of understanding nitric oxide regulation in health and disease. 📖 𝗪𝗮𝗻𝘁 𝘁𝗼 𝗿𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗼𝗻 𝗔𝗗𝗠𝗔? 𝗙𝗼𝗹𝗹𝗼𝘄 𝘁𝗵𝗲 𝗹𝗶𝗻𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀.👇
-
-
🚀 𝗯𝗶𝗼𝗰𝗿𝗮𝘁𝗲𝘀 𝘅 𝗣𝗹𝗮𝘁𝗼𝗺𝗶𝗰𝘀 – 𝗔 𝗴𝗮𝗺𝗲-𝗰𝗵𝗮𝗻𝗴𝗲𝗿 𝗳𝗼𝗿 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 𝗮𝗱𝗼𝗽𝘁𝗶𝗼𝗻! 💫 📢 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗻𝗲𝘄𝘀! biocrates and Platomics are joining forces to help laboratories streamline regulatory compliance and ensure reproducible, high-quality metabolomics workflows. With biocrates’ metabolomics kits now integrated into the PlatoX® platform, labs can effortlessly enhance documentation, accuracy, and efficiency. ✅ Reproducible, high-quality results ✅ Comprehensive, standardized workflow documentation ✅ Faster service with reduced operational complexity 🔍 𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻 𝗳𝗼𝗿 𝗹𝗮𝗯𝘀? The PlatoX® platform simplifies regulatory workflows, providing structured guidance from sample preparation to data analysis. 💡 𝗪𝗮𝗻𝘁 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲? Read the full press release here👉 https://lnkd.in/d-9eAA7M Curious about what Dr. Kriegner Albert and Moritz Seuster have to say? Check out the carousel to read their insights 🌟 #Metabolomics #DataAnalysis #Workflow #Collaboration